The only genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ. Required fields are marked *. Decide whether immediate treatment is necessary or confidently opt for active surveillance. In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. The Oncotype DX GPS test provides insight into how aggressive a tumor might be, which is essential in management planning, when you consider: Dr. Brian Helfand speaks about "Utilizing mpMRI and Genomic Testing for Management of Low- and Intermediate-Risk Prostate Cancer" as part of the LUGPA Virtual Crossfire Series. Read what the Wall Street Journal is saying about the Oncotype DX Genomic Prostate Score test. Genomic Health, Inc. uses your network username and password to login to Box. For patients with clinically low-risk prostate cancer (very low, low, or intermediate NCCN risk) the Oncotype DX Genomic Prostate Score predicts the likelihood of favorable pathology (low-grade [3+3, 3+4], organ-confined disease). By combining our portfolio of products, we are continuing our relentless pursuit of innovative solutions of earlier detection and smarter answers. We will continue to provide the Oncotype DX® tests in your country. Simply login to the online physician portal or order more efficiently by signing up for an online portal account. Requires a very small sample of tumor from a single-needle biopsy core. Exact Sciences is a trademark of Exact Sciences Corporation. Congratulations, you are now logged in successfully to Genomic Health Uk Portal. Your Oncotype DX score can help you decide. The only genomic test proven to predict a patient’s individual benefit from chemotherapy. How does it compare to other genomic tests? By combining our portfolio of products, we are continuing our relentless pursuit of innovative solutions of earlier detection and smarter answers. Assess expression of genes that are reliably recovered and predictive of clinically relevant outcomes across multiple tumor foci. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy. The first and only test to identify patients who will not respond to AR-targeted therapies. The only genomic test proven to predict a patient’s individual benefit from chemotherapy. Part of Genomic Health, Inc.? Find our guide of how to do that on the most popular browsers, here.
Has been validated in multiple contemporary and clinically-relevant patient populations. © National Comprehensive Cancer Network, Inc. 2018. After you click on the link, it will open in a new tab so that you can continue to see the guide and follow the troubleshooting steps if required. Are you trying to login to Genomic Health Uk Portal? This genomic test: Genetic tests typically screen for inherited risk factors and identify changes in chromosomes and genes—which can help in understanding patient risk for having cancer or other diseases. Insurance coverage and financial assistance, Oncotype DX GPS Results: Interpreting the results, AR-V7 Nucleus Detect results: What to expect. If there is an option for viewing your password, use it. The Oncotype DX Genomic Prostate Score (GPS) assay uses genomics to help predict the aggressiveness of prostate tumors. All you need to do is follow these simple instructions below. The only genomic test proven to predict a patient’s individual benefit from chemotherapy. Sign up for Our Healthcare Professional Updates. The era of YOU and YOUR genes is upon us.
However, we will be operating under the Exact Sciences name. Save my name, email, and website in this browser for the next time I comment. See new data for the Oncotype DX Breast Recurrence Score test and how it changes treatment decisions for patients with early-stage breast cancer. Please report and one of our moderators will replace it ASAP. Login Read what the Wall Street Journal is saying about the Oncotype DX Genomic Prostate Score test. How much do ineffective cancer treatments cost the healthcare system? Submit a sample Genomic Health can work directly with the pathology team (or the treating physician) to obtain a sample. For patients with early-stage, ER-positive, HER2-negative, node negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit. While it is rare that people need to follow our troubleshooting guide, there are some instances in which you need to.
Genomic Health | Oncotype DX If you have been unable to activate your account or login please fill in the fields below and click on the submit button to proceed: First Name: Follow the recover your password instructions here.
© 2020 Exact Sciences Corp, All rights reserved. Oncotype DX has helped thousands of women find out. For patients with stage II or II A/B colon cancer whose tumor has been resected, the Oncotype DX Colon Recurrence score can help guide decisions about adjuvant treatment. © Exact Sciences Corporation 441 Charmany Drive Madison, WI 53719Contact Us. However, there is a much easier way. Physician Login Smarter Cancer Care. When Dan's Colon Recurrence Score came back low, he decided against chemotherapy. Accessed February 20, 2018. We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. Society of Surgical Oncology 2020 Virtual Event. Continue to login to Box through your network. Primary study group results were presented at ASCO 2018. At the Genomic Kitchen, we translate this 21st-century health intelligence into a new understanding of . For more information on Exact Sciences visit exactsciences.com. We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. Step 5 – Turn off any Virtual Private Network (VPN) that you may be using. The activity and interaction of genes influences the behavior of a tumor, including its aggressiveness and how likely it is to grow and spread. For patients with ductal carcinoma in situ (DCIS) treated by local excision, with or without tamoxifen, the Oncotype DX Breast DCIS Score can help guide personalized treatment decisions.
Access the SSO 2020 International Conference on Surgical Cancer Care on-demand to view hundreds of oral abstract presentations, videos and posters. From earlier cancer detection to treatment guidance and monitoring, Exact Sciences is helping people face their most challenging decisions with confidence. That can cause unexpected errors such as timeouts. The Genomic Kitchen Prostate biopsy findings often incorrectly represent true prostate pathology; the actual pathology can be more or less aggressive than what is visible in the biopsy sample.6 The Oncotype DX GPS assay is designed to provide precise and predictive information you need to more confidently assess risk and guide treatment decisions for your clinically low- and favorable intermediate-risk prostate cancer patients. Exact Sciences Showcases Continued Progress in Cancer Diagnostics. Learn more about our work and read our blog. If you are trying to log into the physician portal, please visit online.genomichealth.co.uk. The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy. Refines risk based on estimation of likelihood of aggressive disease, and 10-year risk of metastasis and mortality after radical prostatectomy. Exact Sciences is a trademark of Exact Sciences Corporation. Insurance coverage & financial assistance, How to talk to your patient about Oncotype DX GPS. A genomic test that quantifies the risk of recurrence, for insight beyond traditional measures. Step 1 – Make sure that you have an active and reliable internet connection. For more information on our OncotypeDX tests, please visit oncotypeiq.co.uk. Oncotype DX has helped thousands of women find out. To everyone on the front lines of patient care during this time. The Oncotype DX GPS assay is the only genomic test that was designed specifically for use in men with clinically low- or favorable intermediate-risk cancer who are deciding between active surveillance and treatment. Providing there is no one that can not see your password around.
For patients with metastatic castration resistant prostate cancer, the Oncotype DX AR-V7 Nucleus Detect test identifies patients resistant to androgen receptor (AR) therapies such as abiraterone and enzalutamide. How does it compare to other genomic tests?
Download an example of a paper requisition form (PDF) including instructions for more details. Genomic Health, Oncotype DX and Recurrence Score are registered trademarks of Genomic Health, Inc. The era of YOU and YOUR genes is upon us. We want to assure you that our Oncotype DX tests remain readily available and that our laboratory continues to operate. Step 3 – You should now have a “successfully logged in” message. Genomic Health is now part of Exact Sciences. Prostate cancer accounts for over 26,000 cancer related deaths every year.
Has been validated in multiple contemporary and clinically-relevant patient populations. © National Comprehensive Cancer Network, Inc. 2018. After you click on the link, it will open in a new tab so that you can continue to see the guide and follow the troubleshooting steps if required. Are you trying to login to Genomic Health Uk Portal? This genomic test: Genetic tests typically screen for inherited risk factors and identify changes in chromosomes and genes—which can help in understanding patient risk for having cancer or other diseases. Insurance coverage and financial assistance, Oncotype DX GPS Results: Interpreting the results, AR-V7 Nucleus Detect results: What to expect. If there is an option for viewing your password, use it. The Oncotype DX Genomic Prostate Score (GPS) assay uses genomics to help predict the aggressiveness of prostate tumors. All you need to do is follow these simple instructions below. The only genomic test proven to predict a patient’s individual benefit from chemotherapy. Sign up for Our Healthcare Professional Updates. The era of YOU and YOUR genes is upon us.
However, we will be operating under the Exact Sciences name. Save my name, email, and website in this browser for the next time I comment. See new data for the Oncotype DX Breast Recurrence Score test and how it changes treatment decisions for patients with early-stage breast cancer. Please report and one of our moderators will replace it ASAP. Login Read what the Wall Street Journal is saying about the Oncotype DX Genomic Prostate Score test. How much do ineffective cancer treatments cost the healthcare system? Submit a sample Genomic Health can work directly with the pathology team (or the treating physician) to obtain a sample. For patients with early-stage, ER-positive, HER2-negative, node negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit. While it is rare that people need to follow our troubleshooting guide, there are some instances in which you need to.
Genomic Health | Oncotype DX If you have been unable to activate your account or login please fill in the fields below and click on the submit button to proceed: First Name: Follow the recover your password instructions here.
© 2020 Exact Sciences Corp, All rights reserved. Oncotype DX has helped thousands of women find out. For patients with stage II or II A/B colon cancer whose tumor has been resected, the Oncotype DX Colon Recurrence score can help guide decisions about adjuvant treatment. © Exact Sciences Corporation 441 Charmany Drive Madison, WI 53719Contact Us. However, there is a much easier way. Physician Login Smarter Cancer Care. When Dan's Colon Recurrence Score came back low, he decided against chemotherapy. Accessed February 20, 2018. We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. Society of Surgical Oncology 2020 Virtual Event. Continue to login to Box through your network. Primary study group results were presented at ASCO 2018. At the Genomic Kitchen, we translate this 21st-century health intelligence into a new understanding of . For more information on Exact Sciences visit exactsciences.com. We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. Step 5 – Turn off any Virtual Private Network (VPN) that you may be using. The activity and interaction of genes influences the behavior of a tumor, including its aggressiveness and how likely it is to grow and spread. For patients with ductal carcinoma in situ (DCIS) treated by local excision, with or without tamoxifen, the Oncotype DX Breast DCIS Score can help guide personalized treatment decisions.
Access the SSO 2020 International Conference on Surgical Cancer Care on-demand to view hundreds of oral abstract presentations, videos and posters. From earlier cancer detection to treatment guidance and monitoring, Exact Sciences is helping people face their most challenging decisions with confidence. That can cause unexpected errors such as timeouts. The Genomic Kitchen Prostate biopsy findings often incorrectly represent true prostate pathology; the actual pathology can be more or less aggressive than what is visible in the biopsy sample.6 The Oncotype DX GPS assay is designed to provide precise and predictive information you need to more confidently assess risk and guide treatment decisions for your clinically low- and favorable intermediate-risk prostate cancer patients. Exact Sciences Showcases Continued Progress in Cancer Diagnostics. Learn more about our work and read our blog. If you are trying to log into the physician portal, please visit online.genomichealth.co.uk. The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy. Refines risk based on estimation of likelihood of aggressive disease, and 10-year risk of metastasis and mortality after radical prostatectomy. Exact Sciences is a trademark of Exact Sciences Corporation. Insurance coverage & financial assistance, How to talk to your patient about Oncotype DX GPS. A genomic test that quantifies the risk of recurrence, for insight beyond traditional measures. Step 1 – Make sure that you have an active and reliable internet connection. For more information on our OncotypeDX tests, please visit oncotypeiq.co.uk. Oncotype DX has helped thousands of women find out. To everyone on the front lines of patient care during this time. The Oncotype DX GPS assay is the only genomic test that was designed specifically for use in men with clinically low- or favorable intermediate-risk cancer who are deciding between active surveillance and treatment. Providing there is no one that can not see your password around.
For patients with metastatic castration resistant prostate cancer, the Oncotype DX AR-V7 Nucleus Detect test identifies patients resistant to androgen receptor (AR) therapies such as abiraterone and enzalutamide. How does it compare to other genomic tests?
Download an example of a paper requisition form (PDF) including instructions for more details. Genomic Health, Oncotype DX and Recurrence Score are registered trademarks of Genomic Health, Inc. The era of YOU and YOUR genes is upon us. We want to assure you that our Oncotype DX tests remain readily available and that our laboratory continues to operate. Step 3 – You should now have a “successfully logged in” message. Genomic Health is now part of Exact Sciences. Prostate cancer accounts for over 26,000 cancer related deaths every year.